Explore more about: Women's Health

Placenta accreta spectrum (PAS) disorder is a life-threatening condition that occurs when the placenta remains attached to the uterus after childbirth. Now researchers have developed a blood test to identify this condition, enabling early intervention by high-risk pregnancy specialists.

NIBIB selected three winning teams for designs that excel according to four criteria: the significance of the problem being addressed; the impact on clinical care; the innovation of the design; and the ideation process or existence of a working prototype.

The National Institutes of Health has launched a $1 million Technology Accelerator Challenge (TAC) to spur the design and development of non-invasive, handheld, digital technologies to detect, diagnose, and guide therapies for diseases with high global and public health impact.

Learn about Dr. Charolotte Gaydos's scientific accomplishments throughout her career journey and her advice for women scientists.

Learn about Dr. Carla Pugh's scientific accomplishments throughout her career journey and her advice for women scientists.

Women undergoing treatment for ovarian cancer are checked for tumor cells that may have spread to surrounding tissues, but current technologies miss very small metastatic areas. Now a laser microscopy technique is able to identify these regions with great accuracy.

Researchers have developed a new 3D printed device that will make it faster and easier to identify women at risk for premature birth.

Biomedical engineers have developed a smartphone app for anemia screening that can assess blood hemoglobin levels through the window of the user’s fingernail.

A new approach to evaluating the risk of preterm birth has been proposed by analyzing the properties of cervical mucus. The researchers found that cervical mucus from women who delivered their babies early, before 37 weeks, was very different from that of women who delivered later. Read more at MIT News.

A new way to analyze breast cancer MRI data appears to reliably distinguish between patients who would need hormonal treatment versus needing chemotherapy.